Skip to content

US · IMNM · BIOTECHNOLOGY

Immunome, Inc. (IMNM) intrinsic value and stock valuation

$15.69as of 2026-11-21 · Mkt cap 2.39B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Immunome, Inc. DCF and intrinsic value

InvestorsCraft values IMNM with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from IMNM’s statements →

Immunome, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Bothell, WA 98011 immunome.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$6.94M
20182025
Net income
-$-212.39M
20182025
Free cash flow
-$-200.6M
20182025
Total equity
$634.3M+72.7% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$6.94M$9.04M$14M$0.00$0.00
Operating income-$-214.11M-$-305.8M-$-109.53M-$-36.9M-$-25.2M
Net income-$-212.39M-$-292.96M-$-106.81M-$-36.9M-$-24.71M
EPSd-$-2.43M-$-5M-$-5.38M-$-3.04M-$-2.14M
Operating cash flow-$-190.92M-$-110.79M-$-7.57M-$-28.69M-$-18.23M
Capital expenditure-$-9.69M-$-53.51M-$-830K-$-250K-$-80K
Free cash flow-$-200.6M-$-164.3M-$-8.4M-$-28.94M-$-18.3M
Total assets$683.2M$240.2M$148.5M$24.1M$57.9M
Total debt$3.85M$4.83M$1.65M$290K$320K
Net debt-$-649.63M-$-138.52M-$-97.03M-$-20.03M-$-48.91M
Total equity$634.3M$181.2M$119.9M$16.7M$48.2M
Cash and short-term investments$653.5M$217.3M$138.1M$20.3M$49.2M
Income statement
20252024202320222021
Revenue$6.94M$9.04M$14M$0.00$0.00
Cost of revenue$2.96M$0.00$0.00$0.00$0.00
Gross profit$3.99M$9.04M$14M$0.00$0.00
Research and development expenses$174.3M$129.5M$23.1M$23.3M$14.1M
Selling, general and administrative expenses$43.8M$33M$19.7M$13.6M$11.1M
Other expenses$0.00$152.3M$80.8M$0.00$0.00
Operating expenses$218.1M$314.8M$123.6M$36.9M$25.2M
Cost and expenses$221.1M$314.8M$123.6M$36.9M$25.2M
Interest income$11.7M$12.8M$2.72M$10K$10K
Interest expense$0.00$0.00$0.00$10K$10K
Depreciation and amortization$2.96M$2.1M$730K$630K$760K
Ebitda-$-209.44M-$-151.35M-$-28M-$-36.26M-$-23.95M
Operating income-$-214.11M-$-305.8M-$-109.53M-$-36.9M-$-25.2M
Total other income/expenses, net$1.72M$12.8M$2.72M$10K$490K
Income before tax-$-212.39M-$-292.96M-$-106.81M-$-36.9M-$-24.71M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-212.39M-$-292.96M-$-106.81M-$-36.9M-$-24.71M
Weighted average shares outstanding$87.4M$58.6M$19.8M$12.1M$11.5M
Weighted average diluted shares outstanding$87.4M$58.6M$19.8M$12.1M$11.5M
Balance sheet
20252024202320222021
Cash and short-term investments$653.5M$217.3M$138.1M$20.3M$49.2M
Net receivables$0.00$0.00$290K$850K$4.31M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$660.8M$221.3M$144.7M$22.7M$56.6M
Property, plant and equipment, net$17.6M$14.4M$3.64M$960K$850K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$210K$0.00$100K$0.00$100K
Total non-current assets$22.4M$18.9M$3.84M$1.4M$1.29M
Total assets$683.2M$240.2M$148.5M$24.1M$57.9M
Accounts payable$3.34M$14.2M$3.31M$2.4M$3.08M
Short-term debt$0.00$60K$310K$230K$320K
Deferred revenue$0.00$6.94M$10.5M$0.00$0.00
Total current liabilities$45M$54.3M$21.8M$7.33M$9.73M
Long-term debt$3.85M$4.77M$1.34M$60K$0.00
Deferred revenue, non-current$0.00$0.00$5.49M$0.00$0.00
Total non-current liabilities$3.85M$4.77M$6.83M$60K$10K
Capital lease obligations$0.00$4.83M$1.65M$290K$320K
Total liabilities$48.8M$59.1M$28.7M$7.39M$9.74M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-728.16M-$-515.77M-$-222.81M-$-116M-$-79.11M
Accumulated other comprehensive income (loss)$0.00$60K$20K$0.00-$-57.92M
Total equity$634.3M$181.2M$119.9M$16.7M$48.2M
Total investments$210K$74M$39.6M$0.00$100K
Total debt$3.85M$4.83M$1.65M$290K$320K
Net debt-$-649.63M-$-138.52M-$-97.03M-$-20.03M-$-48.91M
Cash flow statement
20252024202320222021
Net income-$-212.39M-$-292.96M-$-106.81M-$-36.9M-$-24.71M
Depreciation and amortization$2.96M$2.1M$730K$630K$760K
Stock-based compensation$25.7M$15.8M$6.22M$5.33M$3.45M
Change in working capital-$-15.23M$14.9M$12M$2.24M$2.78M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-9.16M$9.53M-$-610K-$-680K$1.78M
Net cash provided by operating activities-$-190.92M-$-110.79M-$-7.57M-$-28.69M-$-18.23M
Investments in property, plant and equipment-$-9.69M-$-7.17M-$-830K-$-250K-$-80K
Acquisitions, net$0.00$0.00$9.28M$0.00$0.00
Net cash used for investing activities$60.8M-$-85.06M-$-30.48M-$-250K-$-80K
Common stock issued$640.4M$250M$30K$30K$27.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$640.4M$240.5M$116.4M$30K$27.8M
Net change in cash$510.2M$44.7M$78.4M-$-28.91M$9.46M
Cash at end of period$653.7M$143.5M$98.8M$20.4M$49.3M
Operating cash flow-$-190.92M-$-110.79M-$-7.57M-$-28.69M-$-18.23M
Capital expenditure-$-9.69M-$-53.51M-$-830K-$-250K-$-80K
Free cash flow-$-200.6M-$-164.3M-$-8.4M-$-28.94M-$-18.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Immunome, Inc.

        Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

        CEO
        Clay Siegall
        Employees
        177
        Beta
        2.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Immunome, Inc. (IMNM)?

        Immunome, Inc. (IMNM) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IMNM undervalued?

        IMNM trades at a price of $15.69 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.